# Nuclide record fluciclovine-f18 (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/fluciclovine-f18/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "fluciclovine-f18" ;
  schema:name "Fluciclovine F-18"@en ;
  schema:description "Fluciclovine F-18 was the first PET tracer approved for finding recurrent prostate cancer after treatment (2016), and has been largely superseded since 2020 by PSMA PET."@en ;
  schema:url <https://nuclide.cc/drugs/fluciclovine-f18/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Fluciclovine_(18F)> ;
  owl:sameAs <http://www.wikidata.org/entity/Q25313613> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Axumin> ;
  nuclide:status "approved" ;
  nuclide:tag "gap-fill", "diagnostic" ;
  nuclide:modality "PET radiotracer (synthetic amino acid)" ;
  schema:alternateName "Axumin" ;
  nuclide:approval "US 2016: PET imaging in men with suspected prostate cancer recurrence based on elevated PSA", "EU 2017: Same" ;
  nuclide:related <https://nuclide.cc/isotopes/f-18/>, <https://nuclide.cc/isotopes/ga-68/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/>, <https://nuclide.cc/indications/glioblastoma/> ;
  nuclide:technologies <https://nuclide.cc/technologies/pet/>, <https://nuclide.cc/technologies/pet-ct/> ;
  nuclide:companies <https://nuclide.cc/companies/blue-earth-diagnostics/> ;
  nuclide:terms <https://nuclide.cc/terms/biochemical-recurrence/> .